Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Combination Products Coalition wants guidance: More than half of surveyed members of the Combination Products Coalition, a group of companies in the drug, device and biologics industries, are dissatisfied with existing guidance from their trade associations and FDA on how to move combination products through the regulatory process, according to a CPC/Regulatory Affairs Professional Society (RAPS) survey presented March 26 by regulatory consultant Michael Gross at the Pharma MedDevice meeting in Philadelphia. Of the 32 companies surveyed, 78% were primarily focused on medical device development. Asked which topics they wanted guidance on, coalition members said they were most interested in documents on combination product clinical studies, good manufacturing processes, premarket approval submissions, cross-labeled combination products and adverse event reporting (1"The Gray Sheet" Feb. 18, 2008, p. 3)
You may also be interested in...
Industry Looks To FDA’s New Combo Products Chief For Answers
FDA's Office of Combination Products says it is getting back on track with new leadership in place after months of flux. Industry meanwhile is pushing the office to accelerate the release of rules and guidelines to help companies navigate the relatively new area of regulation
House Republicans Continue To Press FDA On Warning Letter Appeals
FDA leadership needs to review the agency's enforcement dispute resolution process, say ranking Republicans on the House Energy and Commerce Committee
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.